References
- Labardini-Méndez J. Sindromes mieloproliferativos. In: Ruiz-Arguelles GJ. (ed) Fundamentos de Hematologia, 3rd edn. Mexico: Editorial Médica Panamericana, 2003; 261–278.
- Ruiz-Arguelles GJ, Lopez-Martinez B, Lobato-Mendizabal E, Ruiz-Delgado GJ. An addition to geographic hematology: chronic myeloproliferative diseases are infrequent in Mexican Mestizos. Int J Hematol 2002; 75: 499–502.
- Tefferi A, Gilliland G. The JAK2 V617F tyrosine kinase mutationin myeloproliferative disorders: status report and immediate implication for disease classification and diagnosis. Mayo Clin Proc 2005; 80: 947–958.
- Jones AV, Kreil S, Zoi K et al. Widespread occurrence of the JAK2V617F mutation in chronic myeloproliferative disorders. Blood 2005; 106: 2162–2168.
- Ruiz-Arguelles GJ, Garcés-Eisele J, Reyes-Nunez V, Ruiz-Delgado GJ, Navarro-Vazquez M, Gonzalez-Carrillo M. The Janus kinase 2 (JAK2) V617F mutation in hematological malignancies in Mexico. Rev Invest Clin Mex 2006; 58: 458–461.
- Scott LM, Tong W, Levine RL et al. JAK2 exon 12 mutation in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356: 459–468.
- Vannucchi A, Guglielmelli P. Molecular pathophysiology of Philadelphia negative myeloproliferative disorders: beyond JAK2 and MPL mutations. Haematologica 2008; 93: 972–976.
- Ruiz-Arguelles GJ, McArthur JR. Leucemias agudas. In: Ruiz-Arguelles GJ. (ed) Fundamentos de Hematologia, 3rd edn. Mexico: Editorial Médica Panamericana, 2003; 225–245.
- Pons-Estel BA, Catoggio U, Cardiel MH et al. The GLADEL multinational Latin American prospective inception cohort of 1214 patients with systemic lupus erythematosus. Ethnic and disease heterogeneity among 'Hispanics'. Medicine 2004; 83: 1–17.
- Ruiz-Arguelles GJ, Garcés-Eisele J, Reyes-Nunez V, Ruiz-Delgado GJ. Frequencies of the breakpoint cluster region types of the BCR/ ABL fusion gene in Mexican mestizo patients with chronic myelogenous leukemia. Rev Invest OM Mex 2004; 26: 609–614.
- Baxter EJ, Scott LM, Campbell PJ et al. Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061.
- Newton CR, Graham A, Heptinstall LE et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucl Acids Res 1989; 17: 2503–2516.
- Scott LM, Tong W, Levine RL et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 336(5): 459–468.
- Ruiz-Argiielles GJ, Garcés-Eisele J, Reyes-Nifilez V, Ruiz-Delgado GJ, Rosillo C, Camoriano JK. Clearance of the Janus kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia. Am J Hematol 2007; 82: 400–402.
- Ruiz-Argiielles GJ. Algunos aspectos moleculares de los sindromes mieloproliferativos (SMP) crfinicos: Descripcifin de un nuevo SMP: La eritrocitosis primaria. Hematologia: Actualizacifin 2007. Ediciones de la Agrupación Mexicana para el Estudio de la Hematologia A. C. Ciudad de Mexico 2007; 103–110.
- Tefferi A, Thiele J, Orazi A et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytemia and primary myelo-fibrosis: Reccomendations from an ad hoc international expert panel. Blood 2007; 110: 1092–1097.
- Spivak JL, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytemia and primary myelofibrosis: an alternative proposal. Blood 2008; 112: 231–239.
- World Health Organization. Pathology and genetic of tumors of haematopoietic and lymphoid tissues. Lyon: IARC press, 2001.